Stefan Hammerschmidt

3.3k total citations
97 papers, 2.1k citations indexed

About

Stefan Hammerschmidt is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Infectious Diseases. According to data from OpenAlex, Stefan Hammerschmidt has authored 97 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Pulmonary and Respiratory Medicine, 20 papers in Molecular Biology and 12 papers in Infectious Diseases. Recurrent topics in Stefan Hammerschmidt's work include Respiratory Support and Mechanisms (20 papers), Neonatal Respiratory Health Research (11 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (10 papers). Stefan Hammerschmidt is often cited by papers focused on Respiratory Support and Mechanisms (20 papers), Neonatal Respiratory Health Research (11 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (10 papers). Stefan Hammerschmidt collaborates with scholars based in Germany, Italy and Hungary. Stefan Hammerschmidt's co-authors include Hubert Wirtz, Hartmut Kühn, Christian Geßner, Hans Wahn, Hans‐Jürgen Seyfarth, Ulrich Sack, Lothar Engelmann, J. Schauer, Tanja Schirmeister and Klaus Arnold and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Stefan Hammerschmidt

91 papers receiving 2.1k citations

Peers

Countries citing papers authored by Stefan Hammerschmidt

Since Specialization

Citations

This map shows the geographic impact of Stefan Hammerschmidt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefan Hammerschmidt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefan Hammerschmidt more than expected).

Fields of papers citing papers by Stefan Hammerschmidt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stefan Hammerschmidt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefan Hammerschmidt. The network helps show where Stefan Hammerschmidt may publish in the future.

Co-authorship network of co-authors of Stefan Hammerschmidt

This figure shows the co-authorship network connecting the top 25 collaborators of Stefan Hammerschmidt. A scholar is included among the top collaborators of Stefan Hammerschmidt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stefan Hammerschmidt. Stefan Hammerschmidt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1904P Real-world outcomes of nintedanib plus docetaxel for adenocarcinoma NSCLC after failure of first-line immunochemotherapy: The non-interventional VARGADO study 2025 ·Annals of Oncology ·Christian Grohé, Jan Stratmann, Stefan Hammerschmidt, (unknown), Stefan Krüger, (unknown), Wolfgang Schütte, (unknown), (unknown), Thomas Wehler	0
2	Conformational Selection and Induced Fit: The Behavior of Two Homologous Proteases 2023 ·SHILAP Revista de lepidopterología ·(unknown), G. Hinze, Stefan Hammerschmidt, Tanja Schirmeister, Thomas Basché	3
3	Next Generation of Fluorometric Protease Assays: 7‐Nitrobenz‐2‐oxa‐1,3‐diazol‐4‐yl‐amides (NBD‐Amides) as Class‐Spanning Protease Substrates 2023 ·Chemistry - A European Journal ·(unknown), (unknown), (unknown), (unknown), Stefan Hammerschmidt, Robert A. Zimmermann, (unknown), (unknown), Tanja Schirmeister, Fabian Barthels	2
4	Impact of PD-L1 and KRAS status on the efficacy of nintedanib (NIN) + docetaxel (DOC) following treatment with first-line immune checkpoint inhibitor (ICI) + chemotherapy in patients with adenocarcinoma NSCLC: Analysis of cohort C of the non-interventional VARGADO trial. 2023 ·Journal of Clinical Oncology ·Christian Grohé, Thomas Wehler, (unknown), Stefan Hammerschmidt, (unknown), Stefan Krüger, (unknown), Wolfgang Schuette, (unknown), (unknown), (unknown), R. Kaiser	1
5	Identification of novel small-molecular inhibitors of Staphylococcus aureus sortase A using hybrid virtual screening 2022 ·The Journal of Antibiotics ·Galyna P. Volynets, Fabian Barthels, Stefan Hammerschmidt, Olena Moshynets, С. С. Лукашов, (unknown), (unknown), (unknown), Volodymyr G. Bdzhola, (unknown), (unknown), (unknown), S. M. Yarmoluk, Tanja Schirmeister	17
6	Development of Urea-Bond-Containing Michael Acceptors as Antitrypanosomal Agents Targeting Rhodesain 2022 ·ACS Medicinal Chemistry Letters ·Santo Previti, Roberta Ettari, (unknown), (unknown), (unknown), (unknown), Stefan Hammerschmidt, Annika Wagner, (unknown), Sandro Cosconati, Tanja Schirmeister, Maria Zappalà	11
7	Identification, Characterization, and Synthesis of Natural Parasitic Cysteine Protease Inhibitors: Pentacitidins Are More Potent Falcitidin Analogues 2022 ·ACS Chemical Biology ·(unknown), (unknown), Christian Kersten, Maria A. Patras, Michael Kurz, (unknown), Stefan Hammerschmidt, Jenny Legac, Peter Hammann, Andreas Vilcinskas, Philip J. Rosenthal, Tanja Schirmeister, Armin Bauer, Till F. Schäberle	4
8	Fragment-based design of α-cyanoacrylates and α-cyanoacrylamides targeting Dengue and Zika NS2B/NS3 proteases 2022 ·New Journal of Chemistry ·(unknown), (unknown), (unknown), (unknown), (unknown), Stefan Hammerschmidt, (unknown), (unknown), Johnnatan Duarte de Freitas, (unknown), (unknown), Letícia Anderson, Ênio José Bassi, João Xavier de Araújo‐Júnior, Tanja Schirmeister, Edeildo Ferreira da Silva‐Júnior	10
9	1143P Effect of best response to first-line (1L) treatment (tx) on outcomes with second-line (2L) nintedanib (NIN) + docetaxel (DOC) for patients (pts) with lung adenocarcinoma after 1L immune checkpoint inhibitor (ICI) combination therapy 2022 ·Annals of Oncology ·(unknown), Thomas Wehler, (unknown), (unknown), Stefan Hammerschmidt, (unknown), (unknown), (unknown), (unknown), Wolfgang Schuette, Judith Atz, R. Kaiser	2
10	Lead Discovery of SARS-CoV-2 Main Protease Inhibitors through Covalent Docking-Based Virtual Screening 2021 ·Journal of Chemical Information and Modeling ·Giorgio Amendola, Roberta Ettari, Santo Previti, (unknown), Anna Messere, Salvatore Di Maro, Stefan Hammerschmidt, (unknown), Robert A. Zimmermann, Tanja Schirmeister, Maria Zappalà, Sandro Cosconati	41
11	1372P Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) after failure of previous immune checkpoint inhibitor therapy (ICIs): Updated results from the ongoing non-interventional study (NIS) VARGADO (NCT02392455) 2020 ·Annals of Oncology ·Christian Grohé, Wolfgang Gleiber, Siegfried Haas, Stefan Hammerschmidt, Stefan Krüger, (unknown), (unknown), Thomas Wehler, Judith Atz, R. Kaiser	1
12	Proline-Based Allosteric Inhibitors of Zika and Dengue Virus NS2B/NS3 Proteases 2019 ·Journal of Medicinal Chemistry ·(unknown), (unknown), (unknown), Stefan Hammerschmidt, Fabian Barthels, (unknown), (unknown), Fabian Elgner, (unknown), (unknown), Christian Kersten, Werner Kiefer, Jochen Bodem, Eberhard Hildt, Maike Windbergs, Ute A. Hellmich, Tanja Schirmeister	70
13	Ace Inhibitor For Lung Protection During Mechanical Ventilation For Acute Lung Injury-Results Of The Double-Blind, Placebo Controlled, Randomised Acemevent Pilot Study 2017 ·RWTH Publications (RWTH Aachen) ·Hubert Wirtz, Sirak Petros, Kai Zacharowski, (unknown), Evelyn Kuhnt, Norbert Weiler, (unknown), Klaus Schwabe, Stefan Hammerschmidt, Andreas Meier‐Hellmann, A. Weyland, Gernot Marx, Sven Bercker, Dirk Hasenclever, Ulrich Jaschinski	4
14	Preoperative introduction and maintenance immunosuppression therapy of oral-only tacrolimus, mycophenolate mofetil and steroids reduce acute rejection episodes after lung transplantation☆ 2010 ·European Journal of Cardio-Thoracic Surgery ·Hartmuth B. Bittner, Markus J. Barten, Christian Binner, Sven Lehmann, Jens Garbade, Stefan Hammerschmidt, Hubert Wirtz, Friedrich W. Mohr	6
15	Spektrum tuberkulöser Erkrankungen in der pneumologischen Praxis 2008 ·Medizinische Klinik ·Gerhard Hoheisel, (unknown), Jörg Winkler, Christian Geßner, Stefan Hammerschmidt, Hans-Juergen Seyfarth, Silke Reimann, Arne C. Rodloff, Adrian Gillissen, Hubert Wirtz	1
16	Protein kinase C inhibition attenuates hypochlorite-induced acute lung injury 2007 ·Respiratory Medicine ·Stefan Hammerschmidt, Tobias Vogel, (unknown), Christian Geßner, Hans‐Jürgen Seyfarth, Adrian Gillissen, Hubert Wirtz	25
17	Breath condensate nitrite correlates with hyperinflation in chronic obstructive pulmonary disease 2007 ·Respiratory Medicine ·Christian Geßner, Stefan Hammerschmidt, Hartmut Kühn, Gerhard Hoheisel, Adrian Gillissen, Ulrich Sack, Hubert Wirtz	23
18	Exhaled Breath Condensate Nitrite and Its Relation to Tidal Volume in Acute Lung Injury 2003 ·CHEST Journal ·Christian Geßner, Stefan Hammerschmidt, Hartmut Kühn, Tobias Lange, Lothar Engelmann, J. Schauer, Hubert Wirtz	49
19	Acute changes of myocardial creatine kinase gene expression under β-adrenergic stimulation 2000 ·Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease ·Stefan Hammerschmidt, (unknown), (unknown), Hans Wahn, Helga Remkes, Martin J. Lohse, Stefan Neubauer	7
20	Comparable Effects of HOCl and of FMLP-stimulated PMN on the Circulation in an Isolated Lung Model 1997 ·American Journal of Respiratory and Critical Care Medicine ·Stefan Hammerschmidt, Hans Wahn	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact